Target
CD8 T-cells
2 abstracts
Abstract
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.Org: Early Phase Clinical Trials Unit, START Madrid Fundacion Jimenez Diaz, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), University College London Hospital NHS Trust and Great Ormond Street Hospital,
Abstract
CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.Org: City of Hope National Medical Center, John Wayne Cancer Institute, University of Washington and Fred Hutchinson Cancer Research Centre, CARTI Cancer Center, ImaginAb,